Title Launch of KARDIA3 Trial Evaluating Zilebesiran for Uncontrolled Hypertension
On March 5, 2024, Alnylam and Roche announced the launch of the KARDIA-3 Phase 2 trial. This study will assess ...
Tag: ALNY
Senior Research Analyst Maintains Buy Rating on Alnylam Pharmaceuticals with Lowered Price Target
On February 16, 2024, Keay Nakae, a seasoned Senior Research Analyst at Chardan Capital, reaffirmed his optimistic outlook on Alnylam ...
Cantor Fitzgerald Analyst Maintains Neutral Rating and 165 Price Target for Alnylam Pharmaceuticals
On February 15, 2024, Cantor Fitzgerald analyst Olivia Brayer once again expressed a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and ...
Assenagon Asset Management S.A. Makes Striking Investment Move in Alnylam Pharmaceuticals
In a dazzling display of financial finesse, Assenagon Asset Management S.A. has significantly increased its shareholding in Alnylam Pharmaceuticals, Inc. ...
Gulf International Bank UK Ltd Sells 18.6% of Alnylam Pharmaceuticals Holdings Amid Positive Earnings Report
Gulf International Bank UK Ltd, a well-known institutional investor, has recently sold off 18.6% of their holdings in Alnylam Pharmaceuticals, ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
